Johnson & Johnson announced data from two studies highlighting that a Darzalex Faspro based quadruplet regimen demonstrated deep and sustained minimal residual disease negativity rates, and improved long-term progression-free survival in patients with newly diagnosed multiple myeloma, regardless of transplant status. Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (at the 2025 American Society of Clinical Oncology Annual Meeting. “Across multiple studies, the growing body of data on Darzalex-based regimens indicates impressive, deep responses and meaningful progression-free survival in patients with newly diagnosed multiple myeloma, including high risk. These consistent results across patient populations, regardless of transplant eligibility, reinforce the role of Darzalex Faspro as a cornerstone of frontline therapy,” said Jordan Schecter, MD, Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson’s Akeega tablet shows delay in cancer progression
- Bristol deal takes out ‘key’ potential buyer of Summit Therapeutics, says Truist
- Tela Bio appoints Jeffrey Blizard as president, effective immediately
- Johnson & Johnson: Hold Rating Amid Stelara Patent Expiry and Strategic Acquisition
- Needham medtech & diagnostics analyst holds analyst/industry conference call
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue